Loading...

IMUX IMMUNIC INC Other Situations 8-K Filing

MMNC

MX

IMMUNIC INC

(IMUX)

2025 8-K

Show Summary

Show Summary

Rights Offerings

Equity Offerings

Equity Offerings

Clinical Trial Update

CEO Employment Agreement

Financial Results

Positive Trial Results

R&D Day Summary

Management Change

Financial Results Announcement

Appointment of Director

Appointment of COO and Pres...

Annual Meeting of Stockholders

Earnings Reports

Amendment to Increase Autho...

Financial Results and Corpo...

Private Placement

Management Agreements

Financial Results Announcement

Extension of Employment Ter...

Positive Interim Data from ...

Financial Results Announcement

Annual Meeting of Stockholders

Earnings Report

Clinical Trial Results

Appointments, Retirement

Press Release and Presentation

Liquidity Concern at Silico...

Financial Results Announcement

Press Release and Presentation

Management Agreements

External Links:

On April 30, 2025, Immunic, Inc. announced the results from its phase 2 CALLIPER trial for vidofludimus calcium, a drug aimed at treating progressive multiple sclerosis, and shared details in a press release and corporate presentation. A live webinar

AI Assistant

IMMUNIC INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.